OpenAI Science Chief Kevin Weil Launches Warp Sciences With $215 Million for Automated Drug Discovery

Kevin Weil, the former science leader at OpenAI, has launched Warp Sciences, a new AI-powered drug chemistry startup that raised $215 million in Series A funding at a post-money valuation of $865 million. The funding round was led by Lightspeed Venture Partners and included Institutional Venture Partners, Lux Capital, and Premji Invest, along with prominent angel investors including OpenAI Chief Financial Officer Sarah Friar, Coinbase CEO Brian Armstrong, Palantir Chief Technology Officer Shyam Sankar, and LinkedIn co-founder Reid Hoffman.